The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Update in myopia and treatment strategy of atropine use in myopia control
Open accessAbstract
The prevalence of myopia is increasing globally. Complications of myopia are associated with huge economic and social costs. It is believed that high myopia in adulthood can be traced back to school age onset myopia. Therefore, it is crucial and urgent to implement effective measures of myopia control, which may include preventing myopia onset as well as retarding myopia progression in school age children. The mechanism of myopia is still poorly understood. There are some evidences to suggest excessive expansion of Bruch’s membrane, possibly in response to peripheral hyperopic defocus, and it may be one of the mechanisms leading to the uncontrolled axial elongation of the globe. Atropine is currently the most effective therapy for myopia control. Recent clinical trials demonstrated low-dose atropine eye drops such as 0.01% resulted in retardation of myopia progression, with significantly less side effects compared to higher concentration preparation. However, there remain a proportion of patients who are poor responders, in whom the optimal management remains unclear. Proposed strategies include stepwise increase of atropine dosing, and a combination of low-dose atropine with increase outdoor time. This review will focus on the current understanding of epidemiology, pathophysiology in myopia and highlight recent clinical trials using atropine in the school-aged children, as well as the treatment strategy in clinical implementation in hyperopic, pre-myopic and myopic children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mydriasis and glaucoma: exploding the myth. A systematic review
Pandit, R. J., & Taylor, R. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00368.x · Cited by 94 · cited 1×
“The incidence is as low as 1 in 20,000 [75].”
Background
Cited by
IMI Prevention of Myopia and Its Progression
Jonas, J. B., Ang, M., Cho, P., Guggenheim, J. A., He, M. G., Jong, M., Logan, N. S., Liu, M., Morgan, I., Ohno-Matsui, K., et al. (2021) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.62.5.6 · Cited by 475
Self-citationTwo-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study
Yam, J. C., Li, F. F., Zhang, X., Tang, S. M., Yip, B. H. K., Kam, K. W., Ko, S. T., Young, A. L., Tham, C. C., Chen, L. J., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.12.011 · Cited by 317
Prousali, E., Haidich, A.-B., Fontalis, A., Ziakas, N., Brazitikos, P., & Mataftsi, A. (2019) · BMC Ophthalmology · doi:10.1186/s12886-019-1112-3 · Cited by 75
An insight on ophthalmic drug delivery systems: focus on polymeric biomaterials-based carriers
Shafiq, M., Rafique, M., Cui, Y., Pan, L., Do, C.-W., & Ho, E. A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.041 · Cited by 67
Metadata
- Authors
- Wu, P.-C., Chuang, M.-N., Choi, J., Chen, H., Wu, G., Ohno-Matsui, K., Jonas, J. B., & Cheung, C. M. G.
- Venue
- Eye
- Published
- 2018-06-11
- Volume
- 33
- Issue
- 1
- Pages
- 3-13
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- OpenAlex
- W2808259322
- Cited by
- 239
- References
- 1
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update in myopia and treatment strategy of atropine use in myopia control. https://app.cochat.ai/papers/10.1038/s41433-018-0139-7
- The paper
- Wu, P.-C., Chuang, M.-N., Choi, J., Chen, H., Wu, G., Ohno-Matsui, K., Jonas, J. B., & Cheung, C. M. G. (2019). Update in myopia and treatment strategy of atropine use in myopia control. Eye. https://doi.org/10.1038/s41433-018-0139-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.